Covalent Organic Frameworks Assembled Inside Tumor Cells Trigger Cancer Cell Death and Immune Activation

Why It Matters

The technique creates a controllable, immune‑stimulating cancer‑killing modality by merging intracellular polymer synthesis with ferroptosis induction. Its ability to generate a tumor‑specific vaccine could reshape combination‑therapy strategies if delivery challenges are solved.

Key Takeaways

• First intracellular synthesis of crystalline COFs in lysosomes
• COF formation ruptures lysosomes, releasing iron and inducing ferroptosis
• Ferroptosis triggers immune activation and systemic antitumor response
• Intratumoral monomer injection shrinks tumors without observable toxicity

Pulse Analysis

Covalent organic frameworks have been prized for ordered, porous lattices and uses from gas storage to catalysis. Traditional COF synthesis requires high temperatures, toxic solvents, and days of reaction—conditions incompatible with living cells. The University of Macau team exploited lysosomal acidity (pH 4.5‑5.0) to drive imine condensation between TAPB and DMTP at 37 °C. Within six hours, the reaction yielded crystalline UMCOF1, whose honeycomb structure was confirmed by powder X‑ray diffraction and fluorescence imaging. This in‑situ method marks the first creation of an ordered polymer inside a mammalian cell.

Inside lysosomes, the COF particles breach the organelle membrane, spilling ferrous iron into the cytosol. The excess iron catalyzes lipid peroxidation, initiating ferroptosis—a regulated, iron‑dependent cell‑death pathway distinct from apoptosis. Unlike external UMCOF1 nanoparticles, intracellular assembly triggers this cascade, achieving an IC₅₀ of about 44 µM (TAPB equivalent). Ferroptotic death releases damage‑associated molecular patterns such as ATP, HMGB1 and surface‑exposed calreticulin, which activate macrophages and promote dendritic‑cell maturation. In 4T1 mouse models, intratumoral monomer injection reduced tumor mass to 19 % of controls and, when paired with the TLR‑7/8 agonist R848, generated a systemic abscopal response against distant lesions.

The work creates a new class of organelle‑level tools, merging materials science with immuno‑oncology. By coupling a chemically triggered ferroptosis inducer with innate‑immune activation, the platform could underpin personalized cancer vaccines or serve as an adjuvant to checkpoint blockade. Yet the lack of tumor‑specific uptake and reliance on intratumoral delivery pose translational hurdles; systemic use will need targeting ligands or pro‑drug designs to spare healthy tissue. If these delivery challenges are solved, intracellular COF assembly could spawn programmable therapeutics that reshape nanomedicine and solid‑tumor treatment.